Biopharmaceuticals
Did not found any latest news.
News across the web »
May 25, 2012 at 23:31 | Source: Forbes
May 05, 2012 at 04:41 | Source: The Hindu BusinessLine
May 01, 2012 at 18:01 | Source: Wall Street Journal
Apr 30, 2012 at 10:41 | Source: FirstPost
Apr 28, 2012 at 07:36 | Source: The Hindu BusinessLine
Interact & exchange stock tips & market info »
Related News »
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/k3wdh2/chitosanbased_sys) has announced the addition of John Wiley and Sons Ltd's new book "Chitosan-Based Systems for Biopharmaceuticals: Delivery, Targeting and ...
May 22, 2012 at 16:21 | Source: Business Wire
. . . could potentially be useful for the treatment of brain traumas seen in the military, the workplace and in contact sports . . . Scottsdale, AZ (PRWEB) May 26, 2012 QualityStocks would like to highlight RegeneRx, a publicly traded company focused on ...
May 26, 2012 at 17:00 | Source: PRWeb
Gallus BioPharmaceuticals officials said today that they completed a $20 million expansion of clinical manufacturing, equipment and development facilities at its St. Louis facility. The 8,000 square-foot area was changed from a cafeteria into a ...
May 24, 2012 at 18:49 | Source: The Business Journal
QualityStocks News - RegeneRx Biopharmaceuticals TB4 Treatment Shown to Provide Both Neuroprotection
QualityStocks would like to highlight RegeneRx, a publicly traded company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug ...
May 29, 2012 at 09:18 | Source: PR-USA.net
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") reported that data showing that Thymosin beta 4 (Tβ4) "provides both neuroprotection and neurorestoration after traumatic brain injury (TBI)," was ...
May 28, 2012 at 07:03 | Source: News-Medical.Net
Keryx Biopharmaceuticals, Inc. - Product Pipeline Review - 2012 - Our pharmaceuticals report, Keryx Biopharmaceuticals, Inc. - Product Pipeline Review - 2012 provides data on the Keryx Biopharmaceuticals, Inc.'s research and development focus. The report ...
May 17, 2012 at 12:38 | Source: Transworld News
Navidea Biopharmaceuticals (NAVB), a leader in precision diagnostics, is a biopharmaceutical company developing novel radiopharmaceutical imaging agents to help identify the presence and status of disease and enable better diagnostic accuracy, clinical ...
May 21, 2012 at 16:58 | Source: Seekingalpha.com
KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount its $86.25 million. KYTHERA plans to list on the ...
May 17, 2012 at 10:37 | Source: StreetInsider.com
KYTHERA Biopharmaceuticals, a biotech developing an injection to reduce fat around the chin, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The company's sole product candidate, ATX-101, recently ...
May 17, 2012 at 15:30 | Source: NASDAQ
An analyst upgrade last week and renewed investor interest in Keryx Biopharmaceuticals (NASDAQ:KERX) had shares heavily on the move over the past week, a move initially sparked, in part, by positive Phase III data for Zerenex in Japan.
May 16, 2012 at 14:20 | Source: Market Playground